Adaptimmune raises $42M in direct offering

Adaptimmune Therapeutics plc (NASDAQ:ADAP) raised $42 million through the sale of 7 million ADSs at $6 in a registered direct offering to Matrix Capital Management. The price is a 1% discount to the cell therapy company’s close of $6.07 on Tuesday.

Last week, Adaptimmune closed a $65.9 million public offering, in which it sold ADSs for $4.20. The company believes the new cash will fund the company until late 2019 (see BioCentury Extra, March 22)...